VITROLIFE AB SK 02 (WKN: A2JLT3)

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs.It operates through the following geographical segments: EMEA, North and South America, and Asia & Pacific

https://www.marketscreener.com/...recherche=rapide&mots=vitrolife

https://www.vitrolife.com/en/investors/...ity-and-strengthened-offer/  

Hier habe ich wohl leider den Einstieg verpasst:
https://www.marketscreener.com/...y-and-good-organic-growth-27981990/



https://de.marketscreener.com/...type_recherche=rapide&mots=vitro
Vitrolife AB ist ein in Schweden ansässiges Unternehmen, das sich mit Dienstleistungen im Bereich der assistierten Reproduktion beschäftigt. Das Produktportfolio des Unternehmens umfasst G-RINSE, eine Lösung zum Spülen von Kontaktmaterialien, EmbryoGlue, ein rekombinantes menschliches Albumin, ASP, eine Lösung zur Eizellengewinnung und -spülung, und Semen VTS, ein Viskositätsbehandlungssystem, unter anderem. Es bietet auch eine Reihe von Verfahrenslösungen für die Spermienpräparation, Vitrifikation, Embryotransfer und Eizellenentnahme, wie z.B. Temperaturkontrolle, Zustandskontrolle, Gamete-Safe Laborgeräte und Embryonenunterstützung. Das Unternehmen ist unter anderem in Australien, China, Frankreich, Italien, Japan, den Vereinigten Staaten und Großbritannien tätig und führt seine Geschäfte über eine Reihe von Tochtergesellschaften wie Vitrolife Ltd., Vitrolife Pty Ltd. und A.T.S. Srl. durch.  

 

https://www.marketscreener.com/...-UK-distributor-Parallabs-28574142/

Vitrolife : acquires the business of UK distributor Parallabs

05/10/2019 | 06:02am EDT
Vitrolife has today acquired the business of Parallabs Ltd, its distributor in UK and Ireland for EmbryoScope time-lapse systems, and thereby strengthens its presence in UK and Ireland.
Parallabs Ltd has been the Vitrolife UK and Ireland distributor for EmbryoScope time-lapse systems since 2011 and has achieved a high penetration for time-lapse in the market. "The acquisition strengthens Vitrolife in the UK and Ireland by getting access to a wealth of experience from Parallabs, as well as being able to offer customers the complete Vitrolife portfolio from a single sales channel"; says Thomas Axelsson, CEO of Vitrolife AB. "We are delighted to join Vitrolife and together build on the presence and reputation of both companies"; says Phil Branston, majority owner and founder of Parallabs Ltd.
The initial purchase price amounted to GBP 1.9 million. The purchase price was paid in cash and was financed by available cash balances. In addition to the initial purchase price, additional purchase price of GBP 0.5 million may be paid in relation to sales targets. The transaction is expected to be accretive to group revenue of approximately GBP 1 million for a twelve-month period and marginally accretive to EBITDA per share.  

 

https://news.cision.com/vitrolife-ab--publ-/r/...apse-growth,c3028075

Report on Operations 2019: High Time-lapse growth
Thu, Feb 06, 2020 08:30 CET
Fourth quarter
Sales amounted to SEK 409 (320) million, corresponding to an increase of 28 percent in SEK. Sales increased by 21 percent in local currency whereof 11 percent comprised organic growth.
Operating income before depreciation and amortisation (EBITDA) amounted to SEK 160 (135) million, corresponding to a margin of 39 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 7 million.
Net income amounted to SEK 96 (84) million, which gave earnings per share of SEK 0.89 (0.77).
Whole year 2019
Sales amounted to SEK 1 480 (1 151) million, corresponding to an increase of 29 percent in SEK. Sales increased by 22 percent in local currency whereof 12 percent comprised organic growth.
Operating income before depreciation and amortisation (EBITDA) amounted to SEK 587 (479) million, corresponding to a margin of 40 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 37 million.
Net income amounted to SEK 384 (311) million, which gave earnings per share of SEK 3.53 (2.85).
After the end of the period
The Board proposes a dividend of SEK 114 (92) million, corresponding to SEK 1.05 (0.85) per share.
Gothenburg, February 6, 2020
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14  

https://newsclient.omxgroup.com/cdsPublic/...reId=1016647&lang=en

Interim report January–March 2021: Recovery and good profitability
First quarter:

Sales amounted to SEK 379 (334) million, corresponding to an increase of 14 percent in SEK. Sales increased by 20 percent in local currency.
Operating income before depreciation and amortisation (EBITDA) amounted to SEK 163 (116) million, corresponding to a margin of 43 (35) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 10 million.
Net income amounted to SEK 119 (80) million, which gave earnings per share of SEK 1.09 (0.74).  

https://view.news.eu.nasdaq.com/...4013df3e785ead77307038&lang=en

itrolife AB
Financial Statement Release
Fourth quarter and full year report 2022: Strong profitable growth
Fourth quarter

Sales of SEK 855 (514) million, corresponding to an increase of 66% in SEK, whereof organic growth 11%, acquired growth 37% and currency effect 18%. Sales pro forma increased 9% in local currencies (adjusted for business related to Covid-19 tests and divested business).
Consumables increased sales by 23% in SEK, Technologies increased by 36% in SEK, and Genetic Services contributed acquired sales of SEK 192 million.
Including the acquisition we have strong growth in all market regions, Americas 81%, EMEA 31%, Japan Pacific 56% and Asia 32% in local currencies.
Organic growth in local currency (pro forma, adjusted for business related to Covid-19 tests) was in Japan Pacific 24%, Asia 15%, EMEA 6%, and Americas 1%.
Operating income before depreciation and amortisation (EBITDA) was SEK 273 (85) million, corresponding to a margin of 31.9% (16.5%) (pro forma 27.8%). EBITDA per share increased by 196% to SEK 2.02.
Net income was SEK 73 (34) million, resulting in earnings per share of SEK 0.55 (0.26).
Full Year 2022

Sales of SEK 3,234 (1,681) million, corresponding to an increase of 92% in SEK, whereof organic growth 10%, acquired growth 65% and currency effect 18%. Sales pro forma increased 10% in local currencies (adjusted for business related to Covid-19 tests and divested business).
Consumables increased sales by 23% in SEK, Technologies by 16% in SEK, and Genetic Services contributed acquired sales of SEK 1,085 million.
Including the acquisition we have strong growth in all market regions. Americas 177%, EMEA 48%, Japan Pacific 59% and Asia 38% in local currencies.
Organic growth in local currency (pro forma, adjusted for business related to Covid-19 tests) was in Japan Pacific 19%, Asia 16%, EMEA 3%, and Americas 8%.
Operating income before depreciation and amortisation (EBITDA) was SEK 1,050 (544) million, corresponding to a margin of 32.5% (32.4%) (pro forma 32.2%). EBITDA per share increased 63% to SEK 7.75.
Net income was SEK 394 (344) million, resulting in earnings per share of SEK 2.91 (2.97).
Net debt/EBITDA 1.5 (3.2) rolling 12 months.
After the end of the period

Bronwyn Brophy is appointed as new CEO of Vitrolife AB (publ). She will join the company at the latest of 1 August 2023.
The Chairman of the Board, Jón Sigurdsson will assume the position as interim CEO from 1 April 2023.
Board member, Henrik Blomquist, will be the Chairman of the board from 1 April 2023 until the annual general meeting on 27 April 2023.
Current CEO, Thomas Axelsson, will leave his position as CEO, from 31 March 2023.
The Board proposes a dividend of SEK 0.85 (0.80) per share, corresponding to SEK 115 (108) million.
Contact persons:
Thomas Axelsson, CEO, phone: +46 31 721 80 01
Patrik Tolf, CFO, phone: +46 31 766 90 21  

Fourth quarter

Sales of SEK 904 (855) million, an increase of 6%. In local currencies the growth was 5%.
Sales, in local currencies increased by 16% in APAC and 6% in EMEA, while sales in Americas decreased by 5%.
Sales in local currencies increased by 1% in Consumables and 31% in Technologies, while sales in Genetic Services decreased by 2%.
Gross margin increased to 56.9% (54.2).
Operating income before depreciation and amortisation (EBITDA) was SEK 294 (273) million, giving an EBITDA margin of 32.5% (31.9).
Operating cash flow increased to SEK 171 million (166).
An impairment charge of SEK 4,300 million is reported as other operating expenses.
Net income was SEK -4,179 (73) million, resulting in earnings per share of SEK -30.86 (0.55). Excluding the impairment charge, net income increased to SEK 121 million (73), giving earnings per share of SEK 0.89 (0.55).

Full year

Sales of SEK 3,512 (3,234) million, an increase of 9%, or 10% excluding discontinued business. In local currencies, growth was 4% and excluding discontinued business 5%.
Sales, in local currencies and excluding discontinued business, increased by 16% in APAC and 6% in EMEA, while sales in Americas decreased by 3%.
Sales, in local currencies and excluding discontinued business, increased by 9% in Consumables and 11% in Technologies, while sales in Genetic Services decreased by 1%.
Gross margin increased to 56.3% (55.0).
Operating income before depreciation and amortisation (EBITDA) was SEK 1,136 (1,050) million, giving an EBITDA margin of 32.3% (32.5).
Operating cash flow increased to SEK 757 million (636).
An impairment charge of SEK 4,300 million is reported as other operating expenses.
Net income was SEK -3,851 (394) million, resulting in earnings per share of SEK -28.44 (2.91). Excluding the impairment charge, net income was SEK 449 million (394), giving earnings per share of SEK 3.31 (2.91).

Dividend

The Board to propose to the Annual General Meeting a dividend of SEK 135 (115) million, corresponding to SEK 1.00 (0.85) per share. The proposed dividend is based on exclusion of the non-cash impairment charge.